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Summary
Purpose To compare intraocular pressure (IOP)-low-
ering efficacy of prostaglandin analogue, beta-blocker 
and prostaglandin analogue/beta-blocker fixed combi-
nation ophthalmic solution in patients with open-angle 
glaucoma.
Methods In this prospective, multicentre, randomized 
clinical trial, 120 qualifying patients received prostaglan-
din/beta-blocker once daily (n = 40), prostaglandin ana-
logue once daily in the evening (n = 40) or beta-blocker 
twice daily (n = 40). Efficacy was compared across treat-
ment groups over 1 year.
Results Mean IOP at the first visit in the prostaglan-
din group was 26.6  mmHg (SD ± 2.0  mmHg), in beta-
blockers group was 25.9  mmHg (SD ± 1.7  mmHg) and 
in prostaglandin/beta-blockers group was 26.3  mmHg 
(SD ± 2.0  mmHg). Mean IOP at the seventh visit (after 
1 year) in the prostaglandin group was 19.8  mmHg 
(SD ± 1.3 mmHg), in beta-blockers group was 21.3 mmHg 
(SD ± 1.2  mmHg) and in prostaglandin/beta-blockers 
group was 18.4  mmHg (SD ± 1.3  mmHg; range: 16.0–
21.0  mmHg). There was no statistically significant dif-
ference of IOP in both eyes on seventh visit by groups 
(KW = 113.0, p < 0.0001).
Conclusions Over 1 year of treatment, prostaglandin 
analogue/beta-blockers produced clinically relevant 
IOP reductions in patients with open-angle glaucoma 
that were greater than those produced by either prosta-
glandin analogue or beta-blockers alone. Prostaglandin 
analogue/beta-blocker provides both more effective IOP 
reduction than its components and the benefits of once-
daily dosing.
Keywords Intraocular pressure (IOP)  · Fixed combina-
tion  · Open-angle glaucoma  · Prostaglandin analogue  · 
Beta-blockers
Vergleich eines Prostaglandinanalogon, eines 
Beta-Blockers und eines Kombinationspräparates 
von beiden in der Anwendung bei Patienten mit 
primärem Offenwinkelglaukom
Zusammenfassung Vergleich der Wirksamkeit zur 
Augendrucksenkung eines Prostaglandinanalogons, 
eines Beta-Blockers und eines Kombinationspräparates 
in der Anwendung bei primärem Offenwinkelglaukom.




The term glaucoma covers a group of chronic optical 
neuropathies in which ganglion cell damage is associ-
ated with a loss of visual field [1]. Many patients with 
ocular hypertension will develop glaucoma [2–4]. Axonal 
loss is manifested as progressive thinning of the optic 
nerve head’s neuroretinal rim, producing the character-
istic cupping of the nerve. If untreated or inadequately 
treated, glaucoma can lead to blindness.
The prevalence of open-angle glaucoma has recently 
been estimated at 1.9 % in Americans aged >40 years [5]. 
This prevalence equates to approximately 2.2 million 
affected individuals in the United States in 2004, with an 
anticipated increase to 3.3 million by the year 2020  [6]. 
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Worldwide, there will be an estimated 60.5 million peo-
ple with glaucoma by 2010 and 79.6 million by 2020. 
Nearly half of all worldwide glaucoma will occur in 
Asians (47 %), and open-angle glaucoma will account for 
74 % of all glaucoma by 2020; by 2010, 4.5 million peo-
ple worldwide will suffer bilateral blindness from open-
angle glaucoma; this number will increase to 5.9 million 
by 2020 [7].
The goal of treatment in glaucoma and ocular hyper-
tension is to reduce intraocular pressure (IOP) to a tar-
get pressure sufficiently low to prevent glaucomatous 
progression.
As an alternative, a number of different drugs have 
become available over the past 3 decades; the beta-
blocker timolol was introduced in the late 1970s [8]. 
Topical beta-adrenergic blocking agents, such as a timo-
lol, have been widely accepted as a first-line therapy for 
glaucoma and ocular hypertension [9, 10]. Beta-blockers 
reduce IOP by slowing the rate of aqueous humor forma-
tion [11].
Prostaglandin analogues were introduced in the late 
1990s [12] and have proved to be more effective at lower-
ing IOP than beta-blockers [13, 14]. In October 2006, one 
combination was approved: travoprost/timolol (travo-
prost 40 μg and timolol 5 mg/mL). In recent years, a new 
family of drugs, the prostaglandin analogues, has become 
mostly prescribed. Studies have shown that 0.004 % oph-
thalmic solution of travoprost is a potent FP receptor 
agonist in human ciliary muscle and trabecular mesh-
work cells [15, 16]. Unlike beta-blockers, prostaglandin 
analogues reduce IOP by increasing both uveoscleral and 
conventional aqueous humor outflow [17]. Travoprost is 
a prostaglandin analogue product approved for once-
daily dosing in patients with open-angle glaucoma or 
ocular hypertension.
Materials and methods
Patients were eligible for participation in the study if 
they met the following inclusion criteria: primary open-
angle glaucoma (POAG; IOP: 21  mmHg at baseline) 
without pseudoexfoliative or pigmentary glaucoma, 18 
years of age, one ethnic group (all Caucasian) and pre-
viously not treated with any antiglaucoma medications. 
Exclusion criteria were known contraindications to any 
of the study treatments, use of any medicine that might 
affect IOP, abnormal ocular conditions or symptoms 
preventing the patient from entering the study accord-
ing to the investigator’s judgment, pregnancy or lactancy 
and patients with systemic diseases. Patients were also 
excluded if they had a history of chronic or recurrent 
severe inflammatory eye disease; had a history of ocular 
trauma within the preceding 6 months or ocular infec-
tion or inflammation within the preceding 3 months; 
had a history of clinically significant or progressive reti-
nal disease, other severe ocular pathology that would 
have precluded the administration of a topical prosta-
glandin analogue or severe or serious hypersensitivity 
to any components of the study medication; had under-
gone intraocular surgery within the preceding 6 months 
or ocular laser surgery within the preceding 3 months; 
or had a best-corrected visual acuity worse than 0.6, 
anterior chamber angle grade 1 or 2 (measured by goni-
oscopy), a cup-to-disc (C/D) ratio greater than 0.8 or 
severe central visual field loss in either eye. In addition, 
patients could not take part if they were taking glucocor-
ticoids or any additional topical or systemic ocular hypo-
tensive medication; had a history of severe, unstable or 
uncontrolled cardiovascular, hepatic or renal disease; or 
had bronchial asthma or severe chronic obstructive pul-
monary disease.
In all enrolled patients, best-corrected visual acuity 
was more than 0.9 in both eyes, C/D ratio was more than 
0.8 and anterior chamber angle grade was 3 or 4 (mea-
sured by gonioscopy). Patients were without severe cen-
tral visual field defects in both eyes.
The sample was recruited from outpatients attending 
the “Eye Clinic” in the University Clinical Centre in Pris-
tina (Kosovo) and Ljubljana (Slovenia). All participants 
signed the informed consent before any study proce-
dures were conducted.
Patients were assigned to medical interventions at 
random once we tested that patients fulfilled all the 
selection criteria of the study.
To evaluate IOP reduction at 12 months with the three 
medications, it was estimated that 120 cases that met 
all inclusion criteria and none of the exclusion criteria 
should be included (40 patients in each group).
IOP was measured using Goldmann applanation 
tonometer for each eye between 8 a.m. and 10 a.m. at 
baseline (day 0) and six control visits: control 1 (after 1 
day), control 2 (after 7 days), control 3 (after 1 month), 
control 4 (after 3 months), control 5 (after 6 months) and 
control 6 (after 1 year).
The Kruskal–Wallis test was used for statistical analy-
sis. A p-value of < 0.05 was considered to be statistically 
significant.
Results
In this study were included 120 patients with POAG, of 
which 66 or 55.0 % were females and 54 or 45.0 % were 
males. Patients included in the research were divided into 
three groups: (1) prostaglandin group, (2) beta-blockers 
group and (3) prostaglandin/beta-blockers group. In 
each group were 40 patients. By gender, in beta-blockers 
group, in the structure, females were in high level, but 
with c2 test, there was no statistically significant differ-
ence between the genders (c2 = 2.77, p = 0.251, so p > 0.05). 
The mean age of patients in prostaglandin group was 
64.1 years (SD ± 10.7 years; range: 41–87 years). The mean 
age of patients in beta-blockers group was 64.9 years 
(SD ± 10.2 years; range: 43–82 years). The mean age of 
patients in prostaglandin/beta-blockers group was 58.6 
years (SD ± 11.3 years; range: 36–85 years). The analysis 
with one-way analysis of variance showed statistically 
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value between the groups treated with beta-blockers 
and prostaglandin/beta-blockers fixed combination 
therapy (p < 0.001), and also between the groups treated 
with prostaglandin and beta-blockers (p < 0.0001). Mean 
IOP at the sixth visit (after 6 months) in the prostaglan-
din group was 19.0  mmHg (SD ± 1.4  mmHg), in beta-
blockers group was 20.4  mmHg (SD ± 1.2  mmHg) and 
prostaglandin/beta-blockers group was 18.2  mmHg 
(SD ± 1.2  mmHg; range: 16.0–21.0  mmHg). With Krus-
kal–Wallis test, there is statistically significant difference 
of IOP in both eyes on sixth visit by groups (KW = 86.2, 
p < 0.0001). Dunn’s multiple comparison test showed 
statistically significant difference of IOP value between 
the groups treated with beta-blockers and prostaglan-
din/beta-blockers fixed combination therapy (p < 0.001), 
and also between the groups treated with prostaglan-
din and beta-blockers (p < 0.001). Mean IOP at the sev-
enth visit (after 1 year) in the prostaglandin group was 
19.8 mmHg (SD ± 1.3 mmHg), in beta-blockers group was 
21.3  mmHg (SD ± 1.2  mmHg) and prostaglandin/beta-
blockers group was 18.4 mmHg (SD ± 1.3 mmHg; range: 
16.0–21.0 mmHg). With Kruskal–Wallis test, there was no 
statistically significant difference of IOP in both eyes on 
seventh visit by groups (KW = 113.0, p < 0.0001). Dunn’s 
multiple comparison test showed statistically significant 
difference of IOP value between the groups treated with 
prostaglandin and prostaglandin/beta-blockers fixed 
combination therapy (p < 0.001), the groups treated with 
beta-blockers and prostaglandin/beta-blockers fixed 
combination therapy (p < 0.001), and also the groups 
treated with prostaglandin and beta-blockers (p < 0.001; 
Table 2 and Fig. 1).
The mean difference of IOP between first and sec-
ond visit in the patients of prostaglandin group was 
− 3.8  mmHg (SD ± 1.3  mmHg), in the patients of 
significant difference between the mean age by groups 
(T-test = 0.567, p = 0.0003, so p < 0.001; Table 1).
Mean IOP at the first visit in the prostaglandin group 
was 26.6 mmHg (SD ± 2.0 mmHg), in beta-blockers group 
was 25.9  mmHg (SD ± 1.7  mmHg) and prostaglandin/
beta-blockers group was 26.3  mmHg (SD ± 2.0  mmHg). 
With Kruskal–Wallis test, there was no statistically sig-
nificant difference in IOP of both eyes on first visit by 
groups (KW = 5.48, p = 0.064). Mean IOP at the sec-
ond visit (after 2 days) in the prostaglandin group was 
22.8  mmHg (SD ± 1.7  mmHg), in beta-blockers group 
was 23.2  mmHg (SD ± 1.5  mmHg) and prostaglandin/
beta-blockers group was 22.5  mmHg (SD ± 1.8  mmHg). 
With Kruskal–Wallis test, there was no statistically sig-
nificant difference of IOP in both eyes on second visit 
by groups (KW = 5.29, p = 0.07). Mean IOP at the third 
visit (after 7 days) in the prostaglandin group was 
20.4  mmHg (SD ± 2.0  mmHg), in beta-blockers group 
was 21.3  mmHg (SD ± 1.3  mmHg) and prostaglandin/
beta-blockers group was 20.0  mmHg (SD ± 1.9  mmHg). 
With Kruskal–Wallis test, there was statistically sig-
nificant difference of IOP in both eyes on third visit by 
groups (KW = 22.8, p < 0.001). Dunn’s multiple compari-
son test showed statistically significant difference of IOP 
value between the groups treated with beta-blockers 
and prostaglandin/beta-blockers fixed combination 
therapy (p < 0.001), and also between the groups treated 
with prostaglandin and beta-blockers (p < 0.05). Mean 
IOP at the fourth visit (after 1 month) in the prostaglan-
din group was 18.9  mmHg (SD ± 1.6  mmHg), in beta-
blockers group was 20.3  mmHg (SD ± 1.1  mmHg) and 
prostaglandin/beta-blockers group was 18.2  mmHg 
(SD ± 1.7 mmHg; range: 15.0–22.0 mmHg). With Kruskal–
Wallis test, there was statistically significant difference 
of IOP in both eyes on fourth visit by groups (KW = 65.4, 
p < 0.0001). Dunn’s multiple comparison test showed 
statistically significant difference of IOP value between 
the groups treated with beta-blockers and prostaglan-
din/beta-blockers fixed combination therapy (p < 0.001), 
and also between the groups treated with prostaglan-
din and beta-blockers (p < 0.0001). Mean IOP at the fifth 
visit (after 3 months) in the prostaglandin group was 
18.4  mmHg (SD ± 1.5  mmHg), in beta-blockers group 
was 19.9  mmHg (SD ± 1.0  mmHg) and prostaglandin/
beta-blockers group was 17.6  mmHg (SD ± 1.4  mmHg). 
With Kruskal–Wallis test, there was statistically signifi-
cant difference of IOP in both eyes on fifth visit by groups 
(KW = 90.8, p < 0.0001). Dunn’s multiple comparison 
test showed statistically significant difference of IOP 
Table 2 Summary of mean IOP ± standard deviation 
(mmHg) for patients on prostaglandin, beta-blockers or 
prostaglandin/beta-blockers therapy
Visit Prostaglandin Beta-blocker Prostaglandin/
beta-blocker
p-value
Baseline 26.6 ± 2.0 25.9 ± 1.7 26.3 ± 2.0 0.064
Day 2 22.8 ± 1.7 23.2 ± 1.5 22.5 ± 1.8 0.070
Day 7 20.4 ± 2.0 21.3 ± 1.3 20.0 ± 1.9 < 0.0001
Month 1 18.9 ± 1.6 20.3 ± 1.1 18.2 ± 1.7 < 0.0001
Month 3 18.4 ± 1.5 19.9 ± 1.0 17.6 ± 1.4 < 0.0001
Month 6 19.0 ± 1.4 20.4 ± 1.2 18.2 ± 1.2 < 0.0001
Month 12 19.8 ± 1.3 21.3 ± 1.2 18.4 ± 1.3 < 0.0001
Parameter Total Prostaglandin Beta-blocker Prostaglandin/ 
beta-blocker
p-value
N 120 40 40 40
Gender [N (%)]
Male 54 (45.0) 21 (52.5) 14 (35.0) 19 (47.5) 0.251
Female 66 (55.0) 19 (47.5) 26 (65.0) 21 (52.5)
Age [years (mean ± standard deviation)] 62.5 ± 11.0 64.1 ± 10.7 64.9 ± 10.2 58.6 ± 11.3 0.0003
Table 1 The patients’ data
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The loss variance of IOP between first and second 
visit in the patients of prostaglandin group was 14.0 % 
(SD ± 4.3 %), in the patients of beta-blockers group was 
10.4 % (SD ± 3.6 %) and in the patients of prostaglandin/
beta-blockers group was 14.3  mmHg (SD ± 4.9 %). With 
Kruskal–Wallis test, there was statistically significant dif-
ference in percentage of IOP value of both eyes between 
first and second visit by groups (KW = 36.9, p < 0.0001). 
Dunn’s multiple comparison test showed statistically 
significant difference of IOP value between the groups 
treated with beta-blockers and prostaglandin/beta-
blockers fixed combination therapy (p < 0.001), and also 
between the groups treated with prostaglandin and 
beta-blockers (p < 0.001). The loss variance of IOP after 6 
months in the patients of prostaglandin group was 28.2 % 
(SD ± 7.6 %), in the patients of beta-blockers group was 
21.1 % (SD ± 5.5 %) and in the patients of prostaglandin/
beta-blockers group was 30.6 % (SD ± 6.1 %). With Krus-
kal–Wallis test, there was statistically significant differ-
ence in percentage of IOP value of both eyes between first 
and sixth visit by groups (KW = 75.0, p < 0.0001). Dunn’s 
multiple comparison test showed statistically significant 
difference of IOP value between the groups treated with 
beta-blockers and prostaglandin/beta-blockers fixed 
combination therapy (p < 0.001), and also between the 
groups treated with prostaglandin and beta-blockers 
(p < 0.0001). The loss variance of IOP after 1 year in the 
patients of prostaglandin group was 25.0 % (SD ± 7.3 %), 
beta-blockers group was − 2.7  mmHg (SD ± 1.0  mmHg) 
and in the patients of prostaglandin/beta-blockers 
group was − 3.8 mmHg (SD ± 1.4 mmHg). With Kruskal–
Wallis test, there was statistically significant difference 
of IOP value in both eyes between first and second visit 
by groups (KW = 34.46, p < 0.0001). Dunn’s multiple 
comparison test showed statistically significant dif-
ference of IOP value between the groups treated with 
beta-blockers and prostaglandin/beta-blockers fixed 
combination therapy (p < 0.001), and also between the 
groups treated with prostaglandin and beta-blockers 
(p < 0.001). The mean difference of IOP after 6 months 
(from first visit) in the patients of prostaglandin group 
was − 7.6 mmHg (SD ± 2.4), in the patients of beta-block-
ers group was − 5.5 mmHg (SD ± 1.7) and in the patients 
of prostaglandin/beta-blockers group was − 8.1  mmHg 
(SD ± 2.1  mmHg). With Kruskal–Wallis test, there was 
statistically significant difference of IOP value in both 
eyes between first and sixth visit by groups (KW = 58.9, 
p < 0.0001). Dunn’s multiple comparison test showed 
statistically significant difference of IOP value between 
the groups treated with beta-blockers and prostaglan-
din/beta-blockers fixed combination therapy (p < 0.001), 
and also between the groups treated with prostaglandin 
and beta-blockers (p < 0.001). The mean difference of IOP 
after 1 year (from first visit) in the patients of prostaglan-
din group was − 6.8  mmHg (SD ± 2.2), in the patients of 
beta-blockers group was − 4.6  mmHg (SD ± 1.8) and in 
the patients of prostaglandin/beta-blockers group was 
− 7.9 mmHg (SD ± 1.9 mmHg). With Kruskal–Wallis test, 
there was statistically significant difference of IOP value 
in both eyes between first and seventh visit by groups 
(KW = 80.8, p < 0.0001). Dunn’s multiple comparison test 
showed statistically significant difference of IOP value 
between the groups treated with beta-blockers and 
prostaglandin/beta-blockers fixed combination therapy 
(p < 0.001), the groups treated with prostaglandin and 
beta-blockers (p < 0.0001) and also the groups treated 
with prostaglandin and prostaglandin/beta-blockers 
fixed combination therapy (p < 0.001; Table 3 and Fig. 2).
Table 3 Mean IOP ± standard deviation (mmHg) change 
from baseline for patients on prostaglandin, beta-blockers 
or prostaglandin/beta-blockers therapy
Visit Prostaglandin Beta-blocker Prostaglandin/
beta-blocker
p-value
Day 2 − 3.8 ± 1.3 − 2.7 ± 1.0 − 3.8 ± 1.4 < 0.0001
Day 7 − 6.2 ± 1.9 − 4.6 ± 1.5 − 6.3 ± 2.0 < 0.0001
Month 1 − 7.7 ± 1.9 − 5.6 ± 1.6 − 8.2 ± 2.2 < 0.0001
Month 3 − 8.2 ± 2.3 − 6.0 ± 1.8 − 8.7 ± 1.9 < 0.0001
Month 6 − 7.6 ± 2.4 − 5.5 ± 1.7 − 8.1 ± 2.1 < 0.0001
Month 12 − 6.8 ± 2.2 − 4.6 ± 1.8 − 7.9 ± 1.9 < 0.0001   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Fig. 2 Mean IOP ± standard deviation (mmHg) change from 
baseline for patients on prostaglandin (Prost), beta-blockers 
(Beta-B) or prostaglandin/beta-blockers (Prost/Beta-B) 
therapy
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Fig. 1 Summary of mean IOP ± standard deviation 
(mmHg) for patients on prostaglandin (Prost), beta-block-
ers (Beta-B) or prostaglandin/beta-blockers (Prost/Beta-B) 
therapy
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A variety of pharmacologic therapeutic agents are cur-
rently available for the treatment of glaucoma. The aim of 
therapy is to lower IOP, a major causal risk factor in the 
progression of the disease. Topical IOP-lowering medi-
cations can delay or prevent the onset of POAG. IOP-
lowering agents from different pharmacologic classes 
act through distinctly different mechanisms, which allow 
them to be used either for monotherapy or in combina-
tion. The results of the current study show that the fixed 
combination of travoprost/timolol produces greater 
IOP reductions than the positive control, timolol 0.5 %, 
which was administered twice daily. The fixed combi-
nation of travoprost/timolol significantly lowers IOP 
by 7–9  mmHg, which is a 29–33 % reduction relative to 
an average baseline value of 24 mmHg. In addition, the 
fixed combination of travoprost/timolol decreased diur-
nal mean IOP similarly to the concomitant travoprost or 
timolol therapy, with differences in mean IOP ranging 
from 0.4 to 1.1 mmHg. The travoprost/timolol combina-
tion lowered IOP up to 8.6  mmHg [18]. Recent studies 
involving the concomitant administration of beta-block-
ers and prostaglandin analogues have reported further 
reductions in IOP over those achieved with either agent 
dosed as a monotherapy [19].
Several clinical studies that evaluate the clinical effi-
cacy and safety of fixed combination prostaglandin/beta-
blockers have been completed, and this combination is 
safe and stable [20–23]. The first of these by Barnebey 
et al. [21] was a randomized, prospective, multicentre, 
double-masked, parallel group study of 263 patients with 
either open-angle glaucoma or ocular hypertension. 
After a variable washout period during which all ocular 
hypotensive medications were held, the patients were 
randomized to receive either daily (a.m) fixed-combina-
tion travoprost/timolol, with vehicle (placebo) in the eve-
ning, or twice daily timolol or daily (p.m) travoprost, with 
vehicle (placebo) in the morning. They were treated for a 
total of 3 months, while their IOP were monitored at nine 
different time periods. Results showed that fixed-com-
bination travoprost/timolol lowered IOP 1.9–3.3  mmHg 
more that timolol alone, and 0.9–2.4  mmHg more than 
travoprost alone. The adverse event profile was similar 
among all three study arms. IOP reduction from base-
line ranged 32–38 % for the fixed-combination medica-
tion, compared with 29–32 % for travoprost alone and 
25–30 % for timolol alone. These results suggest that 
fixed-combination travoprost/timolol produced clini-
cally relevant IOP reductions greater than either agent 
alone, whereas the incidence of adverse events was 
comparable.
Schuman et al. [20] have reported the IOP-decreasing 
efficacy and safety of travoprost 0.004 %/timolol male-
ate 0.5 % fixed combination eye drop monotherapy and 
those of concomitantly used travoprost 0.004 % eye drops 
and timolol maleate 0.5 % eye drops. This randomized, 
double-masked study involved administration of travo-
prost 0.004 %/timolol maleate 0.5 % fixed combination 
eye drops (155 cases) or travoprost 0.004 % with timolol 
0.5 % maleate eye drops (142 cases) for patients who were 
in the patients of beta-blockers group was 17.5 % 
(SD ± 6.0 %) and in the patients of prostaglandin/beta-
blockers group was 29.9 % (SD ± 5.7 %). With Kruskal–
Wallis test, there was statistically significant difference in 
percentage of IOP value of both eyes between first and 
seventh visit by groups (KW = 99.4, p < 0.0001). Dunn’s 
multiple comparison test showed statistically significant 
difference of IOP value between the groups treated with 
beta-blockers and prostaglandin/beta-blockers fixed 
combination therapy (p < 0.001), the groups treated with 
prostaglandin and beta-blockers (p < 0.0001), and also 
the groups treated with prostaglandin and prostaglan-
din/beta-blockers fixed combination therapy (p < 001; 
Table 4 and Fig. 3).
Discussion
Although there are other risk factors associated with the 
development and progression of glaucoma besides IOP, 
the most widely studied and most important risk factor 
is IOP.
Prostaglandin analogues are today the most pre-
scribed antiglaucoma monotherapy because of their 
potent IOP reduction and good tolerability. Approxi-
mately 40 % of patients treated for glaucoma are unable 
to achieve adequate control of IOP with monotherapy 
[3], and combination of several drugs are very common.
Table 4 Mean (%) change from baseline for patients on 
prostaglandin, beta-blockers or prostaglandin/beta-blockers 
therapy
Visit Prostaglandin Beta-blocker Prostaglandin/
beta-blocker
p-value
Day 2 14.0 ± 4.3 10.4 ± 3.6 14.3 ± 4.9 < 0.0001
Day 7 23.0 ± 6.4 17.5 ± 5.0 23.9 ± 6.7 < 0.0001
Month 1 28.9 ± 6.9 21.4 ± 5.2 30.7 ± 7.0 < 0.0001
Month 3 30.5 ± 7.1 22.8 ± 5.4 32.9 ± 5.7 < 0.0001
Month 6 28.2 ± 7.6 21.1 ± 5.5 30.6 ± 6.1 < 0.0001
Month 12 25.0 ± 7.3 17.5 ± 6.0 29.9 ± 5.7 < 0.0001   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Fig. 3 Loss variance from baseline for patients on prosta-
glandin (Prost), beta-blockers (Beta-B) or prostaglandin/beta-
blockers (Prost/Beta-B) therapy
 
244  Comparison of prostaglandin analogue, beta-blockers and prostaglandin analogue/beta-blockers
original article
1 3
 2. The Advanced Glaucoma Intervention Study (AGIS). 
The relationship between control of intraocular pres-
sure and visual field deterioration. Am J Ophthalmol. 
2000;130:429–40.
 3. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular 
hypertension treatment study: a randomized trail deter-
mines that tropical ocular hypotensive medication delays 
or prevents the onset of primary open-angle glaucoma. 
Arch Ophthalmol. 2002;120:701–13.
 4. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intra-
ocular pressure and glaucoma progression: results from 
the early manifest glaucoma trial. Arch Ophthalmol. 
2002;120:1268–79.
 5. Friedman DS, Wilson MR, Liebmann JM, Fechtner RD, 
Weinreb RN. An evidence-based assessment of risk factors 
for the progression of ocular hypertension and glaucoma. 
Am J Ophthalmol. 2004,138(3):19–31.
 6. Friedman DS, Wolfs RC, O’Colmain BJ, Klein BE, Taylor HR, 
West S, Leske MC, Mitchell P, Congdon N, Kempen J, Eye 
Diseases Prevalence Research Group. Prevalence of open-
angle glaucoma among adults in the United States. Arch 
Ophthalmol. 2004;122(4):532–8.
 7. Quigley HA, Broman AT. The number of people with glau-
coma worldwide in 2010 and 2020. 2006.
 8. Heel RC, Brogden RN, Speight TM, Avery GS. Timolol: a 
review of its therapeutic efficacy in the topical treatment of 
glaucoma. Drugs. 1979;17:38–55.
 9. LeBlanc RP, Krip G. Ophthalmology. 1981;88:244.
10. Zimmerman TJ, Kaufman HE. Arch Ophthalmol. 
1981;95:601.
11. Reiss GR, Brubaker RF. Ophthalmology. 1983;90:1369.
12. Alexander CL, Miller SJ, Abel SR. Prostaglandin analog 
treatment of glaucoma and ocular hypertension. Ann Phar-
macother. 2002;36:504–11.
13. Alm A, Stjernschantz J. Effects on intraocular pressure 
and side effects of 0.005% latanoprost applied once daily, 
evening or morning. A comparison with timolol. Scan-
dinavian Latanoprost Study Group. Ophthalmology. 
1995;102:1743–52.
14. Watson PG. Latanoprost. Two years’ experience of its use in 
the United Kingdom. Latanoprost Study Group. Ophthal-
mology. 1998;105:82–7.
15. Sharif NA, Kelly CR, Crider JY. Invest Ophthalmol Vis Sci. 
2003;44:715.
16. Sharif NA, Crider JY, Husain S, Kaddour-Djebbar I, Ansari 
HR, Abdel-Latif AA. J Ocular Pharm Ther. 2003;19:437.
17. Brubaker RF, Schoff EO, Nau CB, Carpenter SP, Chen K, 
Vandenburgh AM. Am J Ophthalmol. 2001;131:19.
18. AGIS Investigators. The Advanced Glaucoma Intervention 
Study (AGIS). The relationship between control of intraoc-
ular pressure and visual field deterioration. Am J Ophthal-
mol. 2000;130:429–40.
19. Higginbotham EJ, Diestelhorst M, Pfeiffer N, Rouland JF, 
Alm A. The efficacy and safety of unfixed and fixed combi-
nation of latanoprost and other antiglaucoma medications. 
Surv Ophthalmol. 2002;47:133–40.
20. Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a 
fixed combination of travoprost 0.004 %/timolol 0.5 % oph-
thalmic solution once daily for open-angle glaucoma or 
ocular hypertension. Am J Ophthalmol. 2005;140:242–50.
21. Barnebey HS, Orengo-Nania S, Flowers BE, et al. The 
safety and efficacy of travoprost 0.004 %/timolol 0.5 % 
fixed combination ophthalmic solution. Am J Ophthalmol. 
2005;140(1):1–7.
22. Arend KO, Baber T. J Ocul Pharm Ther. 2008;24:414.
23. Hommer A. Eur J Ophthalmol. 2007;17:53. 
diagnosed with POAG or ocular hypertension. The range 
of IOP decrease was 7.3–8.3 mmHg in the group using tra-
voprost 0.004 %/timolol maleate 0.5 % fixed combination 
eye drops and 6.8–8.5 mmHg in the group concomitantly 
using travoprost 0.004 % eye drops with timolol maleate 
0.5 % eye drops; these values were not significantly dif-
ferent [20].
In our study, the mean IOP at the seventh visit (after 
1 year) in the prostaglandin group was 19.8  mmHg 
(SD ± 1.3 mmHg), in beta-blockers group was 21.3 mmHg 
(SD ± 1.2  mmHg) and in prostaglandin/beta-blockers 
group was 18.4  mmHg (SD ± 1.3  mmHg; range: 16.0–
21.0  mmHg). With Kruskal–Wallis test, there was no 
statistically significant difference of IOP in both eyes on 
seventh visit by groups (KW = 113.0, p < 0.0001). The mean 
difference of IOP after 1 year (from first visit) in the patients 
of prostaglandin group was − 6.8 mmHg (SD ± 2.2), in the 
patients of beta-blockers group was − 4.6 mmHg (SD ± 1.8) 
and in the patients of prostaglandin/beta-blockers group 
was − 7.9  mmHg (SD ± 1.9  mmHg). With Kruskal–Wal-
lis test, there was statistically significant difference of 
IOP value in both eyes between first and seventh visit by 
groups (KW = 80.8, p < 0.0001). The loss variance of IOP 
after 1 year in the patients of prostaglandin group was 
25.0 % (SD ± 7.3 %), in the patients of beta-blockers group 
was 17.5 % (SD ± 6.0 %) and in the patients of prostaglan-
din/beta-blockers group was 29.9 % (SD ± 5.7 %). With 
Kruskal–Wallis test, there was statistically significant dif-
ference in percentage of IOP value of both eyes between 
first and seventh visit by groups (KW = 99.4, p < 0.0001).
Conclusion
Well-designed observational studies can identify clini-
cally important differences among therapeutical options 
and provide data on drug effectiveness and safety.
In our study, IOP-lowering effect of fixed combination 
prostaglandin/beta-blocker was superior in comparison 
with monotherapy with travoprost 0.004 % and timolol 
0.5 %, with statistically significant differences in mean 
IOP values after 1, 3 and 6 months of therapy.
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